Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 16/20 | 1.00 |
| ▸ | CCR9 | P51686 | 2/20 | 0.61 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5378162 | 0.91 | CCR2 (1.00) | CCR2GPR35 | |
| SCHEMBL3969276 | 0.90 | CCR2 (0.82) | CCR2CCR9GPR35 | |
| SCHEMBL3960926 | 0.89 | CCR2 (0.80) | CCR2CCR9 | |
| SCHEMBL3957310 | 0.87 | CCR2 (1.00) | CCR2CCR9GPR35 | |
| SCHEMBL6300906 | 0.87 | CCR2 (1.00) | CCR2 | |
| SCHEMBL7008246 | 0.87 | CCR2 (0.81) | CCR2GPR35 | |
| SCHEMBL29845455 | 0.87 | CCR2 (0.81) | CCR2CCR9GPR35 | |
| SCHEMBL6598061 | 0.87 | CCR2 (0.79) | CCR2 | |
| SCHEMBL27658570 | 0.85 | CCR2 (0.82) | CCR2CCR9GPR35 | |
| SCHEMBL6595461 | 0.85 | CCR2 (0.73) | CCR2GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451185-B1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | claimed |
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | claimed |
| CN-1283638-C | Indole-2-formamide compounds as factor Xa inhibitors | AVENTIS PHARMA GMBH (DE) | 2006-11-08 | — | — | CN | claimed |
| US-6906084-B2 | Indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-14 | — | — | US | claimed |
| JP-2005514365-A | — | — | 2005-05-19 | — | — | JP | claimed |
| CN-1589270-A | Indole-2-formamide compounds as factor Xa inhibitors | AVENTIS PHARMA GMBH (DE) | 2005-03-02 | — | — | CN | claimed |
| EP-1451185-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2004-09-01 | — | — | EP | claimed |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | claimed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | claimed |
| US-8846684-B2 | Arbovirus inhibitors and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846684-B2 | Arbovirus inhibitors and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846684-B2 | Arbovirus inhibitors and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-30 | — | — | US | disclosed |
| EP-1451185-B1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | disclosed |
| WO-2012170098-A2 | ARBOVIRUS INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20030119830-A1 | Monocyte chemoattractant protein-1 inhibitor compounds | ZENECA LIMITED | 2003-06-26 | — | — | US | disclosed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | disclosed |
| EP-1314733-A1 | Indole-2-carboxamides as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2003-05-28 | — | — | EP | disclosed |
| US-6441004-B1 | INDOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | ZENECA LIMITED (GB) | 2002-08-27 | — | — | US | disclosed |
| EP-1003504-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | AstraZeneca UK Limited (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999007351-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | ZENECA LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | F12, F5, F2 | CCR2 1071/4885CCR9 1741/4885GPR35 2467/4885 |
| US-20030119830-A1 | Monocyte chemoattractant protein-1 inhibitor compounds | CCL2, CCL11, CCR1 | CCR2 4/4885CCR9 27/4885GPR35 1910/4885 |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | F5, F12, F2 | CCR2 851/4885CCR9 1480/4885GPR35 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.